Home > Boards > US Listed > Biotechs >

GT Biopharma Inc. (GTBP)

GTBP RSS Feed
Add GTBP Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski
Search This Board: 
Last Post: 12/9/2019 11:21:46 AM - Followers: 174 - Board type: Free - Posts Today: 0

OTCQB: GTBP







The Scourge of Cancer

Cancer is the second leading cause of death globally, and responsible for 8.8 million deaths annually.  The economic impact of cancer is increasing. The total annual economic cost of cancer in 2015 was estimated at approximately US$ 2.5 trillion.  Immuno Oncology sits on the leading edge of cancer treatment and research.  In terms of effectiveness it promises to drastically outpace all previous forms of conventional cancer therapy.  Some estimate the Immuno Oncology market at $US 40 Billon and growing.



What is Immuno Oncology?

Immuno Oncology is treatment that recruits and supercharges a person's own immune system components to fight cancer. This can take various forms: the immune system can be stimulated to work harder or smarter in attacking cancer cells, immune system components can be supplied such as man-made immune proteins that attack cancer cells in a targeted way, immune system cells can be "programmed" to only attack very specific cancer cells or even to deliver a "payload" of compounds poisonous to cancer directly and only to the malignant cells. 
 

   




Immuno Oncology Goes Beyond Drawbacks of Conventional Chemotherapy
Conventional chemotherapy poisons the patient's body with the aim of getting the cancer too. Its like spraying a powerful herbicide on your rose garden to get rid of the dandelions. Yes, the weeds will die but the roses will suffer too.

With Immuno Oncology, the cure is not worse than the disease. Many of the harsh and debilitating side effects of chemotherapy are avoided because the agents that kill the cancer are components of the human immune system itself, rather than poison, and the therapy can be precisely targeted to only attack the cancerous cells.  It is truly the next evolutionary leap in cancer treatment.   




GT Biopharma Portfolio



GTBP Therapy Pipeline Highlights

OXS-1550: Treating Lymphoma and Leukemia
When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550, and are killed due to the action of drug’s cytotoxic diphtheria toxin payload.  OXS-1550 has demonstrated success in a Phase 1 human clinical trial in patients with relapsed/refractory B-cell lymphoma or leukemia.

The initial phase 1 study enrolled 25 patients (who) received at least a single course of therapy. The treatment at the higher doses produced objective tumor responses with one patient in continuous partial remission and the second in complete remission. Data from ongoing phase 2 expected in 2H ‘18.

OXS-3550: Treating Leukemia
The OXS-3550 IND will focus on AML, the most common form of adult leukemia with 21,000 new cases expected in 2017 alone (American Cancer Society). These patients will require frontline therapy, usually chemotherapy including cytarabine and an anthracycline, a therapy that has not changed in over 40 years.

OXS-1615 AND OXS-C3550: Treating Solid Tumors
This TetraKE is designed to kill not only the heterogeneous population of cancer cells found in solid tumors but also kill the cancer stem cells that are typically responsible for recurrences.



Other Offerings: Central Nervous System Therapies

GTP-011: Motion Sickness Treatment

GTP-011 is a 72-hour patch for which a patent application has been filed by GTP for the prevention of motion sickness, a well-known syndrome that typically involves nausea and vomiting in otherwise healthy people and that occurs upon exposure to certain types of motion.

PainBrake: Treating Neuropathic Pain 
PainBrake® is a new patented formulation of carbamazepine (Tegretol®) that enables accurate dose fractionation for the treatment of neuropathic pain.  An NIH-supported study estimated that almost 16 million Americans suffer from chronic neuropathic pain. Current drugs provide a useful degree of pain relief in only about half the patients. 

GTP-004: Treating Myasthenia Gravis
GTP-004 is a fixed-dose combination tablet for the treatment of myasthenia gravis. Myasthenia gravis is a chronic autoimmune disease of the neuromuscular junction characterized by muscle weakness. The prevalence of the disease in the United States is estimated at 14 to 20 per 100,000 population, approximately 36,000 to 60,000 cases in the U.S. 

 


GT Biopharma Executive Team: A Who's Who Of The Biotech Sector

"Look at Where Deutsche Bank’s Shawn Cross, Pfizer’s Dr. Raymond Urbanski, Chase Pharmaceutical’s Dr. Kathleen Clarence-Smith, and Barker Davis Founder Geoffrey Davis are making their bets.  Some of the biotech sector’s most affluent and influential individuals are making a move... to GT Biopharma Inc. (GTBP). This up-and-coming biotech company has a therapy pipeline that has attracted some of the industry’s most experienced leaders."




 



Company Website

GTBP Investor's Overview

GTBP News





GTBP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTBP News: Amended Statement of Ownership (sc 13g/a) 01/16/2020 04:31:12 PM
GTBP News: Quarterly Report (10-q) 11/14/2019 04:04:49 PM
GTBP News: Notice of Effectiveness (effect) 10/03/2019 06:01:19 AM
GTBP News: Current Report Filing (8-k) 09/24/2019 08:01:23 AM
GTBP News: Securities Registration Statement (s-1) 09/13/2019 04:13:07 PM
PostSubject
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#18479   Seems like the last promo campaign didn’t do CashBowski 12/09/19 11:21:46 AM
#18478   U2 buddy, compare more notes soon! doogdilinger 11/18/19 11:38:08 AM
#18477   Agreed! Ty, have a great week! Two3 11/18/19 10:48:40 AM
#18476   Same as our last convo, mgmt. just needs doogdilinger 11/18/19 10:34:13 AM
#18475   Thoughts? Two3 11/18/19 10:13:18 AM
#18474   I hear your time is just about up ?????????????????? IB_ 11/15/19 11:00:36 PM
#18473   Me too buddy! Hopefully mgmt. recognizes the need doogdilinger 11/08/19 04:54:30 PM
#18472   Any thoughts? Company needs to keep that news Two3 11/07/19 08:59:11 PM
#18471   Exactly buddy, we'll see how this plays out doogdilinger 11/05/19 01:04:30 PM
#18470   Yes Sir! Balls in Mgmt hands now, hoping Two3 11/04/19 11:12:37 AM
#18469   GM Two3 buddy, early profit takers churned out doogdilinger 11/04/19 10:33:40 AM
#18468   Morning $$$GTBP$$$ Two3 11/04/19 09:35:09 AM
#18467   U2 doogdilinger 11/01/19 04:19:09 PM
#18466   Have a good weekend! Two3 11/01/19 12:01:35 PM
#18465   Yep, no time like the present to go doogdilinger 11/01/19 01:13:25 AM
#18464   GTBP 20 day crossed up through the 50 doogdilinger 11/01/19 01:11:16 AM
#18463   Ahhh, hello my friend... Good times ahead! Been Two3 11/01/19 01:07:50 AM
#18462   Gotta luv the sell on news opportunities these doogdilinger 11/01/19 01:04:50 AM
#18461   If the stock gets near the pre promo SB16 10/28/19 12:01:23 PM
#18460   me too matchmyask 10/28/19 11:46:23 AM
#18459   mikeski74 what does the $ by the GTBP europa7 10/25/19 01:04:36 PM
#18458   Added here this morning :) LowFloatLopes 10/25/19 12:07:42 PM
#18457   Good Morning $GTBP mikeski74 10/25/19 08:00:47 AM
#18455   Volume is going back to normal (i.e., very SB16 10/24/19 09:53:08 AM
#18454   GM mikeski74 10/24/19 09:40:38 AM
#18453   GM mikeski doogdilinger 10/24/19 09:40:23 AM
#18452   GM $GTBP mikeski74 10/24/19 09:15:24 AM
#18451   Anyone else puzzled and more than a little SB16 10/24/19 02:59:45 AM
#18450   Per Midam’s own disclaimers, we’ll very likely see SB16 10/24/19 02:42:23 AM
#18449   Nice additional snag buddy! Textbook solidification day ahead doogdilinger 10/23/19 04:15:05 PM
#18447   10k @ .20 always appreciated choo choo. $$$GTBP$$$ Two3 10/23/19 02:46:34 PM
#18446   Little expected profit takin' dippin' ahead of the doogdilinger 10/23/19 02:02:32 PM
#18443   Churnin out a few profit takers & solidifying doogdilinger 10/23/19 11:11:44 AM
#18441   Ty Two3 10/23/19 11:09:29 AM
#18440   Here you go buddy \m/ doogdilinger 10/23/19 11:08:29 AM
#18439   You should be happy then! Due Diligence is Two3 10/23/19 10:59:50 AM
#18438   Ray who? And I’ve done my due SB16 10/23/19 10:57:14 AM
#18436   Is that you, Tony? SB16 10/23/19 10:48:58 AM
#18435   GM doogdilinger, volume continues, what are next levels Two3 10/23/19 10:41:58 AM
#18434   Oh Steve, $$$GTBP$$$ positive news flow, maturing biotech Two3 10/23/19 10:39:54 AM
#18433   Um, Timber... SB16 10/23/19 09:47:19 AM
#18432   GM BISHOP, GTBP mgmt.'s definitely proceeding with their doogdilinger 10/23/19 09:37:05 AM
#18431   GM Two3:) doogdilinger 10/23/19 09:35:14 AM
#18430   Haven't been here in a long time but BISHOP ABC 10/23/19 09:35:13 AM
#18429   GM mikeski! doogdilinger 10/23/19 09:34:49 AM
#18428   GM $GTBP mikeski74 10/23/19 06:58:40 AM
#18427   MONSTA statement day today, as GTBP is finally doogdilinger 10/22/19 04:20:01 PM
#18425   .32 cents next target! doogdilinger 10/22/19 02:35:16 PM
#18424   of course SmallCapStockGuy 10/22/19 01:29:10 PM
#18423   Yeppers MOMO! Crushed the .229 resistance level like doogdilinger 10/22/19 01:18:06 PM
PostSubject